Elanco Animal Health Inc
NYSE:ELAN
Intrinsic Value
Elanco Animal Health, Inc. innovates, develops, manufactures, and markets products for pets and farm animals. [ Read More ]
The intrinsic value of one
ELAN
stock under the Base Case scenario is
19.6
USD.
Compared to the current market price of 13.04 USD,
Elanco Animal Health Inc
is
Undervalued by 33%.
Elanco Animal Health Inc's market capitalization is 6.4B USD.
ELAN stock price is 13.04 USD.
ELAN stock price (13.04 USD) is 33% less than its Intrinsic Value (19.6 USD).
ELAN stock price (13.04 USD) is 56% less than its Relative Value (29.4 USD). Open Relative Valuation
ELAN has upside potential of 39% compared to the average analyst price target.
Open Wall St Estimates
ELAN's Revenue has grown by 0% over the past 12 months.
ELAN has positive Free Cash Flow for the last twelve months.
ELAN's ROIC (Return on Invested Capital) has increased in the last 3 years from 0% to 2%.
ELAN's Revenue is forecast to grow at a rate of 4% per year over the next 3 years.
ELAN's D/E (Debt to Equity) is very low and is equal to 0.92.
ELAN has positive Operating Income for the last twelve months.
ELAN's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 2%.
ELAN's Revenue has been growing by 11% per year for the last 3 years.
ELAN's ROE (Return on Equity) has significantly decreased in the last 3 years from -8% to -18%, and is approaching profitability.
ELAN's long-term assets (14B USD) exceed its long-term liabilties (8B USD).
ELAN has a very low three-year average ROIC (Return on Invested Capital): 2%. The company is not efficient at using invested capital to generate operating income.
ELAN's ROE (Return on Equity) for the past 12 months is negative and is equal to -18%.
ELAN has negative Net Income for the last twelve months.
ELAN has positive Gross Profit for the last twelve months.
ELAN has negative three-year average ROE (Return on Equity): -7%. The company is not efficient at transforming stockholders' equity into net income.
ELAN's short-term assets (3B USD) exceed its short-term liabilties (1B USD).
ELAN has positive Net Debt. This means that the company has more debt (6B USD) than cash and short-term investments (352m USD).
ELAN's Altman Z-Score is very low and is equal to 0.85.
Valuation Backtest
Elanco Animal Health Inc
Run backtest to discover the historical profit from buying and selling
ELAN
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Elanco Animal Health Inc
Balance Sheet Decomposition
Elanco Animal Health Inc
| Current Assets | 3.4B |
| Cash & Short-Term Investments | 352m |
| Receivables | 1B |
| Other Current Assets | 2B |
| Non-Current Assets | 11B |
| Long-Term Investments | 26m |
| PP&E | 1B |
| Intangibles | 9.6B |
| Other Non-Current Assets | 315m |
| Current Liabilities | 1.2B |
| Accounts Payable | 270m |
| Accrued Liabilities | 157m |
| Other Current Liabilities | 814m |
| Non-Current Liabilities | 6.9B |
| Long-Term Debt | 5.7B |
| Other Non-Current Liabilities | 1.2B |
Earnings Waterfall
Elanco Animal Health Inc
|
Revenue
|
4.4B
USD
|
|
Cost of Revenue
|
-1.9B
USD
|
|
Gross Profit
|
2.5B
USD
|
|
Operating Expenses
|
-2.2B
USD
|
|
Operating Income
|
326m
USD
|
|
Other Expenses
|
-1.6B
USD
|
|
Net Income
|
-1.2B
USD
|
Free Cash Flow Analysis
Elanco Animal Health Inc
ELAN Profitability Score
Profitability Due Diligence
Elanco Animal Health Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
Score
Elanco Animal Health Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
ELAN Solvency Score
Solvency Due Diligence
Elanco Animal Health Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Score
Elanco Animal Health Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ELAN Price Targets Summary
Elanco Animal Health Inc
According to Wall Street analysts, the average 1-year price target for
ELAN
is 18.11 USD
with a low forecast of 14.14 USD and a high forecast of 21 USD.
Ownership
ELAN Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ELAN Price
Elanco Animal Health Inc
| Average Annual Return | -17.52% |
| Standard Deviation of Annual Returns | 26.49% |
| Max Drawdown | -78% |
| Market Capitalization | 6.4B USD |
| Shares Outstanding | 492 970 000 |
| Percentage of Shares Shorted | 3.08% |
ELAN News
Last Important Events
Elanco Animal Health Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Elanco Animal Health Inc
Company Profile
Elanco Animal Health Inc
Country
Industry
Market Cap
Dividend Yield
Description
Elanco Animal Health, Inc. innovates, develops, manufactures, and markets products for pets and farm animals. The company is headquartered in Greenfield, Indiana and currently employs 9,000 full-time employees. The company went IPO on 2018-09-20. The firm is focused in delivering products and services to prevent and treat disease in farm animals and pets. Its portfolio serves animals across its core species consisting of dogs, cats and cattle, poultry, swine, sheep and aqua. The company offers products in two primary categories: Pet Health and Farm Animal. Its Pet Health portfolio is focused on parasiticides, vaccines and therapeutics. Its parasiticide portfolios in the pet health sector include species and formulations, with products that protect pets from worms, fleas and ticks. Its over-the-counter treatments include Seresto, Advantage, Advantix, Advocate, Credelio, Interceptor Plus and Trifexis. Its farm animal portfolio consists of products designed to prevent, control and treat health challenges primarily focused on cattle. Its products include medicated feed additives, antibiotics, vaccines, such as Rumensin and Baytril. Its poultry products are Maxiban and others
Contact
IPO
Employees
Officers
The intrinsic value of one
ELAN
stock under the Base Case scenario is
19.6
USD.
Compared to the current market price of 13.04 USD,
Elanco Animal Health Inc
is
Undervalued by 33%.
You don't have any saved screeners yet
